Editorial correspondence
Contact the CJC-1295 Ipamorelin Monograph
For corrections, source suggestions, and editorial questions about the published record.
Editorial correspondence
This page is for editorial correspondence about the CJC-1295 Ipamorelin monograph — corrections to a citation, a study we should add, or a question about how we have read the literature. We welcome notes that sharpen the accuracy of the record. Because this is an editorial publisher and not a clinic, we cannot answer questions about personal use, dosing, sourcing, or health decisions, and we do not provide medical advice. If you have a health question, consult a qualified healthcare professional.
What we can and cannot help with
We can help with: pointing us to a peer-reviewed study, flagging a broken or mis-attributed reference, or clarifying a mechanism we have summarized. We cannot help with: recommending a dose or protocol, advising whether anyone should use these compounds, sourcing or purchasing, or any individual medical matter. The monograph carries no protocol and endorses no use; correspondence is held to the same line. Neither CJC-1295 nor ipamorelin is FDA-approved, and nothing here is dosed, dispensed, prescribed, or sold.
Send a message
Use the form below to reach the editorial team. Please include the page and reference number your note concerns so we can verify it against the source quickly. We read correspondence about the literature; we do not respond to requests for medical guidance or product sourcing.